Skip to main content

Table 1 Statistical power based on average number of febrile attacks

From: Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial

  

TCZ groupa

1

1.5

2

Placebo groupa

5.5

91.5

80

65.8

6

94.5

86.1

73.3

6.5

96.2

90

79.8

  1. TCZ Tocilizumab
  2. aThe average number of febrile attacks during 24 weeks in each group is shown